source
- Alpha-emitting radiopharmaceuticals gain attention in metastatic castration-resistant prostate cancerDr. Johann De Bono and Dr. Pedro Barata reviewed the current landscape of alpha-emitting radiopharmaceuticals for patients with metastatic castration-resistant prostate cancer (mCRPC). They highli…
- Experts discuss the evolving role of radiopharmaceuticals in advanced prostate cancerDr. Pedro Barata and Dr. Johann de Bono wrapped up a series on metastatic castration-resistant prostate cancer by looking ahead to how radiopharmaceutical treatments may shape care. They highlight…